CAC
IONS icon

Cowen and Company’s Ionis Pharmaceuticals IONS Stock Holding History

Cowen and Company’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-13,700
Closed -$1K – 702
2022
Q1 		$1K Buy
13,700
+3,700
+37% +$121K ﹤0.01% 589
2021
Q4 		$1K Sell
10,000
-4,700
-32% -$148K ﹤0.01% 627
2021
Q3 		$13K Buy
+14,700
New +$554K ﹤0.01% 512
2021
Q2 		– Sell
-40,300
Closed -$33K – 634
2021
Q1 		$33K Buy
+40,300
New +$2.25M ﹤0.01% 421
2020
Q4 		– Sell
-16,500
Closed -$16K – 465
2020
Q3 		$16K Buy
+16,500
New +$917K ﹤0.01% 372
2020
Q2 		– Sell
-2,000
Closed -$13K – 429
2020
Q1 		$13K Buy
+2,000
New +$111K ﹤0.01% 343

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Cowen and Company's IONS Position: Q1 2024 in Review

Cowen and Company sold out of Ionis Pharmaceuticals (IONS) in Q1 2024, closing a stake of 51,415 shares — an estimated $2.6M sold.

Cowen and Company first reported a position in IONS in Q1 2020 and held it in 9 quarters. The position peaked at $2.6M in Q4 2023. 362 funds tracked by Wall St. Rank hold IONS as of Q1 2024.

  • Cowen and Company reported no remaining Ionis Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
  • Cowen and Company sold 51,415 Ionis Pharmaceuticals shares in Q1 2024, an estimated $2.6M.
  • Cowen and Company first reported a position in Ionis Pharmaceuticals in Q1 2020 and held it in 9 quarters.
  • Cowen and Company's Ionis Pharmaceuticals position peaked at $2.6M in Q4 2023.
  • 362 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2024.

Based on Cowen and Company's 13F filing for Q1 2024, filed 3 May 2024.